These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 17100315)

  • 21. Variable region-connected, dimeric fraction of intravenous immunoglobulin enriched in natural autoantibodies.
    Vassilev TL; Bineva IL; Dietrich G; Kaveri SV; Kazatchkine MD
    J Autoimmun; 1995 Jun; 8(3):405-13. PubMed ID: 7576001
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Isoagglutinin reduction by a dedicated immunoaffinity chromatography step in the manufacturing process of human immunoglobulin products.
    Hoefferer L; Glauser I; Gaida A; Willimann K; Marques Antunes A; Siani B; Wymann S; Widmer E; El Menyawi I; Bolli R; Spycher M; Imboden M
    Transfusion; 2015 Jul; 55 Suppl 2():S117-21. PubMed ID: 26174889
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intravenous immunoglobulin: regulatory perspectives on use and supply.
    Farrugia A; Poulis P
    Transfus Med; 2001 Apr; 11(2):63-74. PubMed ID: 11299022
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Validation and implementation of Planova™ BioEX virus filters in the manufacture of a new liquid intravenous immunoglobulin in China.
    Ma S; Pang GL; Shao YJ; Hongo-Hirasaki T; Shang MX; Inouye M; Jian CY; Zhu MZ; Yang HH; Gao JF; Xi ZY; Song DW
    Biologicals; 2018 Mar; 52():37-43. PubMed ID: 29434001
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The dynamics of contract plasma fractionation.
    Farrugia A; Scaramuccia D
    Biologicals; 2017 Mar; 46():159-167. PubMed ID: 28236560
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunochemical characterization of intravenous immunoglobulin preparations.
    Rüfenacht R; Morell
    Allergol Immunopathol (Madr); 1991; 19(5):197-200. PubMed ID: 1811416
    [No Abstract]   [Full Text] [Related]  

  • 27. Quantifying the thrombogenic potential of human plasma-derived immunoglobulin products.
    Germishuizen WA; Gyure DC; Stubbings D; Burnouf T
    Biologicals; 2014 Sep; 42(5):260-70. PubMed ID: 25096922
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pathogen inactivation and removal procedures used in the production of intravenous immunoglobulins.
    Kempf C; Stucki M; Boschetti N
    Biologicals; 2007 Mar; 35(1):35-42. PubMed ID: 16581263
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Research and development commitments in an integrated plasma collection and plasma fractionation environment.
    Radosevich M
    Semin Thromb Hemost; 1998; 24(2):157-61. PubMed ID: 9579637
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pathogen safety of human C1 esterase inhibitor concentrate.
    Gröner A; Nowak T; Schäfer W
    Transfusion; 2012 Oct; 52(10):2104-12. PubMed ID: 22413956
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Plasma fractionation in the world: current status].
    Burnouf T
    Transfus Clin Biol; 2007 May; 14(1):41-50. PubMed ID: 17499539
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The autoreactivity of therapeutic intravenous immunoglobulin (IVIG) preparations depends on the fractionation methods used.
    Djoumerska I; Tchorbanov A; Pashov A; Vassilev T
    Scand J Immunol; 2005 Apr; 61(4):357-63. PubMed ID: 15853919
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparative study of the anti-inflammatory effect of two intravenous immunoglobulin preparations manufactured by different processes.
    Elluru S; Duong Van Huyen JP; Prost F; Delignat S; Bayry J; Ephrem A; Siberil S; Misra N; Lacroix-Desmzes S; Kazatchkine MD; Kaveri SV
    Immunol Lett; 2006 Sep; 107(1):58-62. PubMed ID: 16952403
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Aggregates in monoclonal antibody manufacturing processes.
    Vázquez-Rey M; Lang DA
    Biotechnol Bioeng; 2011 Jul; 108(7):1494-508. PubMed ID: 21480193
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intravenous immunoglobulin: a review.
    Eibl MM; Wedgwood RJ
    Immunodefic Rev; 1989; 1 Suppl():1-42. PubMed ID: 2698646
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Blood protein technological industrial developments as a mirror of fundamental studies bgy the Institute of Biochemistry of the Ukrainian National Academy of Sciences].
    Volkov GL; Andrianov SI; Horoshnykova TV; Borysevych OS; Gavryliuk OS
    Ukr Biokhim Zh (1999); 2000; 72(4-5):109-21. PubMed ID: 11200439
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Preparation of commercial quantities of a hyperimmune human intravenous immunoglobulin preparation against an emerging infectious disease: the example of pandemic H1N1 influenza.
    Kreil TR; Mc Vey JK; Lei LS; Camacho L; Wodal W; Kerschbaum A; Segura E; Vandamme E; Gavit P; Ehrlich HJ; Barrett PN; Baker DA
    Transfusion; 2012 Apr; 52(4):803-9. PubMed ID: 21981280
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Donor screening reduces the isoagglutinin titer in immunoglobulin products.
    Siani B; Willimann K; Wymann S; Marques Antunes A; Widmer E
    Transfusion; 2015 Jul; 55 Suppl 2():S95-7. PubMed ID: 26174905
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vitro and in vivo characterization of a new enterovirus type 71-specific human intravenous immunoglobulin manufactured from selected plasma donors.
    Cao RY; Han JF; Jiang T; Tian X; Yu M; Deng YQ; Qin ED; Qin CF
    J Clin Virol; 2011 Aug; 51(4):246-9. PubMed ID: 21641277
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Gamma irradiation of intravenous immunoglobulin.
    Drohan WN; Miekka SI; Griko YV; Forng RY; Stafford RE; Hill CR; Mann DM; Burgess WH
    Dev Biol (Basel); 2004; 118():133-8. PubMed ID: 15645683
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.